К. М. Фигурин

ORCID: 0000-0001-9158-837X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Testicular diseases and treatments
  • Renal cell carcinoma treatment
  • Bladder and Urothelial Cancer Treatments
  • Urinary and Genital Oncology Studies
  • Neuroblastoma Research and Treatments
  • Multiple and Secondary Primary Cancers
  • Glioma Diagnosis and Treatment
  • Sarcoma Diagnosis and Treatment
  • Renal and related cancers
  • Renal and Vascular Pathologies
  • Immunotherapy and Immune Responses
  • Cancer Immunotherapy and Biomarkers
  • Immune Cell Function and Interaction
  • Cancer Research and Treatments
  • Urologic and reproductive health conditions
  • Pediatric Urology and Nephrology Studies
  • Cancer Diagnosis and Treatment
  • Ovarian cancer diagnosis and treatment
  • Adrenal and Paraganglionic Tumors
  • Cardiac, Anesthesia and Surgical Outcomes
  • Esophageal Cancer Research and Treatment
  • Genital Health and Disease
  • Venous Thromboembolism Diagnosis and Management
  • Head and Neck Cancer Studies
  • Urological Disorders and Treatments

Ministry of Health of the Russian Federation
2020-2021

Cancer Research Center
1996-2020

Russian Cancer Research Center NN Blokhin
1993-2020

Academy of Medical Sciences
1996

Objective: to assess the results of nephrectomy, thrombectomy in RCC patients with level III–IV tumor venous thrombosis and without cardiopulmonary bypass. Materials methods. Medical data 167 consecutive underwent nephrectomy N.N. Blokhin Russian Cancer Research Center between 1998 2012 were collected. Right side was 122 (73.1 %), left – 42 (25.1 bilateral 3 (1.8 %) cases. The extent thrombus defined as intrahepatic 82 (49.1 supradiaphragmatic 85 (50.9 (intrapericardial 44 (26.3 intraatrial...

10.17650/1726-9776-2016-12-4-21-34 article EN Cancer Urology 2016-01-01

Objective: to develop an effective and safe surgical technique for the treatment of patients with renal cell carcinoma invasive tumor venous thrombosis inferior vena cava (IVC). Materials methods. The study included 75 underwent at N.N. Blokhin Russian Cancer Research Center between 1995 2017. median age was 57 years (range: 32–72 years). All were diagnosed RCC levels II–IV; them, 55 (73.3 %) had complete IVC obstruction mature collaterals. Twenty- seven (26.0 regional, 37 (49.3 – distant...

10.17650/1726-9776-2018-14-2-15-25 article EN Cancer Urology 2018-07-07

Aim : to evaluate results of partial nephrectomy for patients with a solitary kidney performed at the N.N. Blokhin Cancer Center. Materials and methods medical data 131 tumors underwent Department Urology Russian Research Center from 1980 2015 were collected. Median age was 57 (26–75) years, maleto-female ratio 1:1.2. RENAL score 7.0 ± 2.4. In all cases, chronic disease initially diagnosed (stage III – 30 (22.9 %), stage IV–V 0 (0 %)). follow-up 55 (6–386) months. Results . The rate...

10.17650/1726-9776-2017-13-2-27-35 article EN Cancer Urology 2017-01-01

e16063 Background: Cisplatin- and etoposide-based CT allows curing the majority of patients (pts) with metastatic germ cell tumor. There are limited data concerning importance maintenance DI during iCT. In retrospective study we analyzed role iCT on NSGCT. Methods: 589 chemotherapy-naïve pts advanced NSGCT received induction from 1987 to 2006 in our center. We compared all who relapsed after (147 pts) 159 randomly sampled without relapses. During classical E 500 P (24%) or BE (76%) regimens....

10.1200/jco.2009.27.15_suppl.e16063 article EN Journal of Clinical Oncology 2009-05-20

4748 Background: Based on the results of Horwich A. et al. (Proc Am Soc Clin Oncol 1997, No 1137) a phase II study efficacy and toxicity C-BOP-3BEP regimen in treatment NSGCT pts with poor prognosis had been performed. Methods: CT-naïve (IGCCCG) have received C-BOP as follows: weeks 1 3: cisplatin (P) 20 mg/m2 days 1–5, vincristine (O) 2 mg day 1, bleomycin (B) 15 1; 4: P 40 carboplatin AUCx3 B mg/day continuous i.v. infusion 1–5 O 5 6: 1. On week 7, 10 13 BEP (P etoposide 100 1,3,5) was...

10.1200/jco.2004.22.90140.4748 article EN Journal of Clinical Oncology 2004-07-15

Objective : to compare the results of partial (PN) and radical nephrectomy (RN) in patients with renal parenchymal tumors nephrometric PADUA index ≥8 and/or RENAL ≥7 functioning contralateral kidney. Materials methods . Medical data 114 consecutive cell carcinoma (RCC) cT1–3aN0M0 kidney were included into study: 57 (50.0 %) persons undergone PN for (the main group), RN control group). The groups comparable regards demographic characteristics, parameters, morphological tumor features,...

10.17650/1726-9776-2019-15-4-39-49 article EN Cancer Urology 2020-01-16

Seminal vesicle tumors are very rare malignancies which not diagnosed in daily clinical oncology practice. Primary malignant seminal difficult to define due the lack of specific symptoms early stages disease. Another obstacle proper diagnosis is frequent invasion surrounding organs, especially prostate, rectum and bladder differentiate. Very often detect. Digital rectal examination as well transrectal ultrasound scan (US) could reveal a bulky mass retrovesical space. Computed tomography...

10.17650/1726-9776-2015-11-4-89-95 article EN Cancer Urology 2015-12-10

4748 Background: Based on the results of Horwich A. et al. (Proc Am Soc Clin Oncol 1997, No 1137) a phase II study efficacy and toxicity C-BOP-3BEP regimen in treatment NSGCT pts with poor prognosis had been performed. Methods: CT-naïve (IGCCCG) have received C-BOP as follows: weeks 1 3: cisplatin (P) 20 mg/m2 days 1–5, vincristine (O) 2 mg day 1, bleomycin (B) 15 1; 4: P 40 carboplatin AUCx3 B mg/day continuous i.v. infusion 1–5 O 5 6: 1. On week 7, 10 13 BEP (P etoposide 100 1,3,5) was...

10.1200/jco.2004.22.14_suppl.4748 article EN Journal of Clinical Oncology 2004-07-15

Objective : to assess the early and late functional results of partial nephrectomy in patients with solitary functioning kidney tumors. Materials methods . Medical data 131 consecutive parenchymal tumor, who had undergone at N. Blokhin Russian Cancer Research Center, were analyzed. The median age was 57 (26–75) years. All diagnosed tumor (median RENAL score 7.0 ± 2.4 PADUA 9.0 2.2). baseline glomerular filtration rate (GFR) 74 (33–159) ml/min/1.73 m2 (30 (22.9 %) – stage III chronic disease...

10.17650/1726-9776-2017-13-3-46-53 article EN Cancer Urology 2017-01-01

10.17650/1726-9776-2006-2-3-5-11 article EN DOAJ (DOAJ: Directory of Open Access Journals) 2020-02-01

Приводится описание редкого наблюдения больного с синхронным двусторонним опухолевым поражением мочевыделительной системы.

10.17650/1726-9776-2016-12-1-102-105 article RU Cancer Urology 2016-04-18

Paraganglioma is hormonally active tumor originating from chromaffin tissue of sympathoadrenal system that secrete large amounts catecholamines. the urinary bladder a rare neoplasm, constituting approximately 0.06 % all tumors this localization. It believed disease arises embryonic remnants cells in sympathetic plexus detrusor. Up to 10 these have malignant origin. Diagnosis and tactics treatment patients with paragangliomas presents certain difficulties. The article describes 2 clinical...

10.17650/1726-9776-2016-12-3-102-108 article EN Cancer Urology 2016-01-01
Coming Soon ...